(Q35829958)

10 August 2017

1 reference

title

Novel therapies for myelodysplastic syndromes. (English)

1 reference

10 August 2017

2

Hagop M Kantarjian

1 reference

10 August 2017

1

Stefan Faderl

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

101

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

226-241

1 reference

Proposals for the classification of the myelodysplastic syndromes

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Myelodysplastic syndrome is not merely "preleukemia"

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

The myelodysplastic syndrome(s): a perspective and review highlighting current controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Epidemiological and etiological aspects of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Occupation and leukemia: a population-based case-control study in Iowa and Minnesota

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Risk factors for myelodysplastic syndromes: a case-control study in Greece

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Immunophenotypic clustering of myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Problems in the classification of CMML--dysplastic versus proliferative type.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

The WHO classification of MDS does make a difference

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Recent advances in biology and treatment of myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.20381

1 reference

7 January 2021

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Pilot study of low-dose interleukin-11 in patients with bone marrow failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Immunosuppressive therapy for hypoplastic myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Mechanisms and future directions for angiogenesis-based cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Antiangiogenic therapy in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

The fundamental role of epigenetic events in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Cellular differentiation, cytidine analogs and DNA methylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of differe

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20381

7 January 2021

Identifiers

DOI

10.1002/CNCR.20381

1 reference

10 August 2017

1 reference